Eltrombopag in Children

---

Author Details : Priti S. Mehta

Volume : 1, Issue : 1, Year : 2015

Article Page : 20-23

Suggest article by email

Get Permission

---

Abstract

Immune (idiopathic) thrombocytopenic purpura (ITP), a disease of low platelet count affects as many as 5 in 100,000 children each year.¹ Being a self-remitting illness patients usually don’t need aggressive treatment. However  up to 30 percent of children are diagnosed with chronic ITP (cITP) experiencing persistent disease at 1 year from beginning of symptomatology.^2,3,4 Patients with paediatric cITP are at a high risk of severe bleeding due to low platelet counts. Line of treatment for cITP in children include rituximab, high dose dexamethasone therapy, dapsone, multiple single agents, splenectomy and last but not the least thrombopoeitin receptor agonists like eltrombopag which is approved by U.S. FDA for use in children. Eltrombopag being an oral drug compared to other modalities has shown very promising results in paediatric patients with cITP, has attained a consistent platelet response for 6 of 8 weeks compared to placebo (39.7% vs 3.4% respectively, p < 0.001).

Keywords: Eltrombopag, Chronic immune thrombocytopenic purpura, Thrombopoietin –receptor agonist
Modalities of Treating Chronic ITP in Children^5,6,7

1.        Rituximab

2.        High dose dexamethasone therapy

3.        Dapsone

4.        Numerous agents such as azathioprine, danazol, interferon, mycophenolate mofetil,^,cyclosporine, antiCD52 monoclonal antibody

5.        Splenectomy

6.        Thrombopoeitin receptor agonists

 

How to cite : Mehta P S, Eltrombopag in Children. IP Int J Med Paediatr Oncol 2015;1(1):20-23

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.